Overexpression of Pygopus‑2 is required for canonical Wnt activation in human lung cancer

Zhou,Shi‑Yong; Xu,Mei‑Lin; Wang,Shao‑Qing; Zhang,Fang; Wang,Lei; Wang,Hua‑Qing

doi:10.3892/ol.2013.1691

Overexpression of Pygopus‑2 is required for canonical Wnt activation in human lung cancer

Authors:
- Shi‑Yong Zhou
- Mei‑Lin Xu
- Shao‑Qing Wang
- Fang Zhang
- Lei Wang
- Hua‑Qing Wang
View Affiliations

Affiliations: Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of Pathology, Tianjin Chest Hospital, Tianjin 300051, P.R. China, Longyao Hospital, Longyao County, Xingtai, Hebei 055350, P.R. China, Tsinghua University Graduate School at Shenzhen, Division of Life and Health Sciences, Shenzhen, Guangdong 518055, P.R. China, Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: November 19, 2013 https://doi.org/10.3892/ol.2013.1691
Pages: 233-238

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common cause of cancer‑related mortality worldwide. It is necessary to improve the understanding of the molecular mechanisms involved in lung cancer in order to develop more effective therapeutics for the treatment of this fatal disease. The canonical Wnt signaling pathway has been known to be important in a number of cancer types, including lung cancer. Pygopus (Pygo) is a recently identified downstream component of the Wnt signaling pathway required for β‑catenin/T‑cell factor (TCF)‑dependent transcription. However, the role of Pygo in lung cancer remains to be elucidated. The present study showed that Pygo2 is overexpressed in human lung cancer tissue samples and cell lines. Expression levels of Pygo2 were found to correlate with cytosolic β‑catenin protein levels in the samples examined. Co‑immunofluorescent staining showed that Pygo2 protein accumulated in the nuclei and colocalized with nuclear β‑catenin in lung cancer cell lines expressing Pygo2. To investigate the functional importance of the Pygo2 overexpression in lung cancer, short hairpin RNA (shRNA) was used to knockdown Pygo2 mRNA in lung cancer cells expressing the gene. Pygo2 shRNA was observed to inhibit cell proliferation and decrease β‑catenin/TCF‑dependent transcriptional activity in vitro. Furthermore, Pygo2 shRNA significantly suppressed lung cancer xenograft models in vivo (P<0.05). These results suggested that Pygo2 is a putative therapeutic target for human lung cancer and overexpression of Pygo2 may be important for aberrant Wnt activation in lung cancer.

View Figures

View References

1	Sekido Y, Fong KM and Minna JD: Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta. 1378:F21–F59. 1998.PubMed/NCBI
2	Smith W and Khuri FR: The care of the lung cancer patient in the 21st century: a new age. Semin Oncol. 31(2 Suppl 4): S11–S15. 2004. View Article : Google Scholar : PubMed/NCBI
3	Klaus A and Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 8:387–398. 2008. View Article : Google Scholar : PubMed/NCBI
4	Ohgaki H, Kros JM, Okamoto Y, Gaspert A, Huang H and Kurrer MO: APC mutations are infrequent but present in human lung cancer. Cancer Lett. 207:197–203. 2004. View Article : Google Scholar
5	Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R and Yokota J: Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer. 30:316–321. 2001. View Article : Google Scholar : PubMed/NCBI
6	He B, You L, Uematsu K, et al: A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia. 6:7–14. 2004. View Article : Google Scholar : PubMed/NCBI
7	You L, He B, Xu Z, et al: Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 23:6170–6174. 2004. View Article : Google Scholar : PubMed/NCBI
8	Winn RA, Marek L, Han SY, et al: Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem. 280:19625–19634. 2005. View Article : Google Scholar
9	Uematsu K, He B, You L, Xu Z, McCormick F and Jablons DM: Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 22:7218–7221. 2003. View Article : Google Scholar : PubMed/NCBI
10	Fukui T, Kondo M, Ito G, et al: Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene. 24:6323–6327. 2005. View Article : Google Scholar : PubMed/NCBI
11	Wissmann C, Wild PJ, Kaiser S, et al: WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol. 201:204–212. 2003. View Article : Google Scholar : PubMed/NCBI
12	Mazieres J, He B, You L, et al: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 64:4717–4720. 2004. View Article : Google Scholar : PubMed/NCBI
13	Ueda M, Gemmill RM, West J, et al: Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer. 85:64–68. 2001. View Article : Google Scholar : PubMed/NCBI
14	You L, He B, Xu Z, et al: An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 64:5385–5389. 2004. View Article : Google Scholar : PubMed/NCBI
15	Jackson AL, Bartz SR, Schelter J, et al: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 21:635–637. 2003. View Article : Google Scholar : PubMed/NCBI
16	Pongracz JE and Stockley RA: Wnt signalling in lung development and diseases. Respir Res. 7:152006. View Article : Google Scholar : PubMed/NCBI
17	Fukukawa C, Nagayama S, Tsunoda T, Toguchida J, Nakamura Y and Katagiri T: Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma. Oncogene. 28:1110–1120. 2009. View Article : Google Scholar : PubMed/NCBI
18	Jin X, Jeon HY, Joo KM, et al: Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res. 71:3066–3075. 2011. View Article : Google Scholar
19	Rhee CS, Sen M, Lu D, et al: Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene. 21:6598–6605. 2002. View Article : Google Scholar : PubMed/NCBI
20	Tanaka S, Akiyoshi T, Mori M, Wands JR and Sugimachi K: A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proc Natl Acad Sci USA. 95:10164–10169. 1998. View Article : Google Scholar : PubMed/NCBI
21	To KF, Chan MW, Leung WK, et al: Alterations of frizzled (FzE3) and secreted frizzled related protein (hsFRP) expression in gastric cancer. Life Sci. 70:483–489. 2001. View Article : Google Scholar : PubMed/NCBI
22	Ueno K, Hazama S, Mitomori S, et al: Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br J Cancer. 101:1374–1381. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zeng G, Germinaro M, Micsenyi A, et al: Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia. 8:279–289. 2006. View Article : Google Scholar : PubMed/NCBI
24	DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P and Rubinfeld B: The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res. 67:5371–5379. 2007. View Article : Google Scholar : PubMed/NCBI
25	de la Roche M, Rutherford TJ, Gupta D, et al: An intrinsically labile alpha-helix abutting the BCL9-binding site of beta-catenin is required for its inhibition by carnosic acid. Nat Commun. 3:6802012.PubMed/NCBI
26	Takada K, Zhu D, Bird GH, et al: Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med. 4:148ra1172012. View Article : Google Scholar : PubMed/NCBI